SI-Bone Inc (SIBN)
NASDAQ:SIBN
Want to see SIBN full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.14Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong commercial and financial momentum: double-digit top-line growth, industry-leading gross margins (~79.8%), improving profitability (Adjusted EBITDA up >440%), record physician engagement, multiple product launches, and a meaningful potential reimbursement tailwind from proposed CMS DRG changes. These positives are balanced by remaining GAAP net losses, negative free cash flow (though improved), near-term cash flow variability from HQ buildout and CapEx, and execution/timing risks around partner rollouts and ASP mix pressure. On balance, the strength in growth, margins, guidance raise, product pipeline, and reimbursement outlook outweigh the execution and timing headwinds.Company Guidance
Revenue Growth (Q1 2026)
Worldwide revenue of $52.6M, up 11.2% year-over-year; U.S. revenue $49.3M, up ~10%; international revenue $3.3M, up 33.9%.
Raised Full-Year Guidance
Full-year 2026 revenue guidance increased to $230.0M–$233.0M, implying ~14%–16% year-over-year growth (midpoint ~15%).
Strong Gross Margins
Gross profit $41.9M (+11.3%); gross margin ~79.8% for the quarter (flat year-over-year) and full-year gross margin target raised ~100 bps to ~79%.
Improving Profitability
Adjusted EBITDA of $2.5M in Q1, representing over 440% improvement vs $0.5M in Q1 2025; net loss narrowed to $4.3M ($0.10 per diluted share) from $6.5M ($0.15).
Operating Leverage / Controlled OpEx
Operating expenses grew ~4.1%, significantly below revenue growth (~11.2%), reflecting ~2.5x operating leverage and disciplined spend on commissions, training and pipeline investments.
Cash and Liquidity Position
Exited Q1 with $144.7M in cash and marketable securities, providing runway for R&D, launches, and commercial expansion.
Free Cash Flow Improvement
Free cash flow was negative $3.4M in Q1, a 50.7% improvement versus the prior-year period (seasonality noted due to commission true-ups and bonuses).
Physician Engagement and Commercial Productivity
Record 1,650 active physicians in the quarter (+17% year-over-year); 20 consecutive quarters of double-digit physician growth; 14 consecutive quarters of double-digit territory productivity growth; revenue per territory $2.2M (+11% YoY) with 89 quota-carrying territory managers.
Product Launches and Pipeline Momentum
Launched Intra TI in Q1; introduced TNT TORQ in Europe and TORQ in Australia; third Breakthrough Device progressing with V&V nearly complete, targeting 510(k) filing in early Q3 and commercial launch in Q4.
Strategic Partnership with Smith & Nephew
Completed first phase of field rollout with Smith & Nephew in April; training and capacity rollout expected substantially complete by end of Q2; revenue contribution anticipated to begin in Q3 and accelerate into Q4.
Favorable Reimbursement Developments
CMS proposed new DRG families for extensive/complex spinal fusion procedures (including cases that use Granite), potentially increasing average hospital payment by up to ~$50K per procedure if finalized (effective Oct 1, 2026), which could materially support Granite adoption.
International Commercial Traction
International revenue growth of 33.9% driven by accelerating demand for iFuse TORQ across Europe and Australia and early enthusiasm for TNT in Europe; international now tracking as an accretive growth contributor.
SIBN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SIBN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $11.61 | $13.90 | +19.72% |
Feb 23, 2026 | $15.62 | $15.29 | -2.11% |
Nov 10, 2025 | $15.68 | $18.22 | +16.20% |
Aug 04, 2025 | $17.90 | $16.00 | -10.61% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does SI-Bone Inc (SIBN) report earnings?
SI-Bone Inc (SIBN) is schdueled to report earning on Aug 10, 2026, After Close (Confirmed).
What is SI-Bone Inc (SIBN) earnings time?
SI-Bone Inc (SIBN) earnings time is at Aug 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SIBN EPS forecast?
SIBN EPS forecast for the fiscal quarter 2026 (Q2) is -0.15.